Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

Nordic firms have outperformed those from the rest of Europe over the past decade. In all four countries, listed ...

With a Goldilocks economy and a bull market charging into a second year, 2024 shaped up to be a good year for investors. Now, ...

Loomis Sayles, an investment management company, released its “International Growth Fund” third quarter 2024 investor letter.

The pharmaceutical industry in Denmark has grown rapidly in recent years. This paper discusses the macroeconomic impact of the pharmaceutical sector. The analysis focuses on Novo Nordisk, the leading ...

The largest project underway is Novo Nordisk’s $4.1 billion expansion in Johnston County ... Amgen is also growing its local ...

Stocks signaled another rough day of trading on Friday after the House of Representatives voted against a Trump-backed ...

Denmark-based Novo Nordisk told The Progress-Index in an email ... Signs outside of AMPAC’s 600,000 square-foot facility on Normandy Drive, however, have been changed to reflect the new owners.

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it ...

COPENHAGEN: Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged on Friday (Dec 20) after it announced disappointing ...

Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock.